Impact of Valproate on Angiogenesis and Histone Deacetylation in Bladder Cancer

Launched by STATE UNIVERSITY OF NEW YORK - UPSTATE MEDICAL UNIVERSITY · Nov 29, 2012

Keywords

ClinConnect Summary

Bladder cancer is the fourth most common cancer in the United States with over 60,000 new cases each year. It can usually be treated initially by insertion of an endoscope into the bladder and surgically removing the tumor, a procedure known as cystoscopy and trans-urethral resection of bladder tumor (TURBT). For most patients this procedure will successfully remove all of the detectable tumor. Unfortunately over 40% of all patients will develop a cancer recurrence in less than two years and all patients remain at increased risk of recurrence for the remainder of their lives. This risk requ...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patient over the age of 21
• • 2. Bladder tumor suspected or confirmed
• • 3. ECOG status 0 to 2
• 4. Premedication Lab values:
• • Absolute Neutrophil Count \>750 cells/m3 AST/ALT less than 1.5xN Amylase less than 1.5xN Platelet Count \> 125,000 PT/PTT \> 1.3xN Hemoglobin \> 8gm/dL Creatinine less than 1.5xN
• Exclusion Criteria:
• • 1. Allergy to valproic acid
• • 2. Concurrent chemotherapy
• • 3. Pre-menopausal women
• • 4. Active systemic infection (HepatitisB,C)
• • 5. Coagulation disorders
• • 6. Concurrent medication: Tolbutamide, Warfarin, Zidovudine, Benzodiazepine, Clonazepam, Diazepam, Any anti-convulsant therapy
• • 7. Seizure disorder
• • 8. Dementia
• • 9. History of Pancreatitis
• • 10. HIV diagnosis/treatment
• • 11. Liver disease/dysfunction